- Histone Deacetylase Inhibitors Induce Growth Arrest and Differentiation in Uveal Melanoma
[作者:Landreville, S; Agapova, OA; Matatall, KA; Kneass, ZT; Onken, MD; Lee, RS; Bowcock, AM; Harbour, JW,期刊:Clinical Cancer Research, 页码:408-416 , 文章类型: Article,,卷期:2012年18-2]
- Purpose: Metastasis is responsible for the death of most cancer patients, yet few therapeutic agents are available which specifically target the molecular events that lead to metastasis. We recently showed that inactivat...
- Leflunomide Induces Apoptosis in Fludarabine-Resistant and Clinically Refractory CLL Cells
[作者:Dietrich, S; Kramer, OH; Hahn, E; Schafer, C; Giese, T; Hess, M; Tretter, T; Rieger, M; Hullein, J; Zenz, T; Ho, AD; Dreger, P; Luft, T,期刊:Clinical Cancer Research, 页码:417-431 , 文章类型: Article,,卷期:2012年18-2]
- Purpose: Environmental conditions in lymph node proliferation centers protect chronic lymphocytic leukemia (CLL) cells from apoptotic triggers. This situation can be mimicked by in vitro stimulation with CD40 ligand (CD4...
- Anti-EGFR Antibody Cetuximab Enhances the Cytolytic Activity of Natural Killer Cells toward Osteosarcoma
[作者:Pahl, JHW; Ruslan, SEN; Buddingh, EP; Santos, SJ; Szuhai, K; Serra, M; Gelderblom, H; Hogendoorn, PCW; Egeler, RM; Schilham, MW; Lankester, AC,期刊:Clinical Cancer Research, 页码:432-441 , 文章类型: Article,,卷期:2012年18-2]
- Purpose: Osteosarcoma and Ewing's sarcoma are the most common bone tumors in children and adolescents. Despite intensive chemotherapy, patients with advanced disease have a poor prognosis, illustrating the need for alter...
- Bexarotene via CBP/p300 Induces Suppression of NF-kappa B-Dependent Cell Growth and Invasion in Thyroid Cancer
[作者:Cras, A; Politis, B; Balitrand, N; Darsin-Bettinger, D; Boelle, PY; Cassinat, B; Toubert, ME; Chomienne, C,期刊:Clinical Cancer Research, 页码:442-453 , 文章类型: Article,,卷期:2012年18-2]
- Purpose: Retinoic acid (RA) treatment has been used for redifferentiation of metastatic thyroid cancer with loss of radioiodine uptake. The aim of this study was to improve the understanding of RA resistance and investig...
- Targeting Tumor-Associated Endothelial Cells: Anti-VEGFR2 Immunoliposomes Mediate Tumor Vessel Disruption and Inhibit Tumor Growth
[作者:Wicki, A; Rochlitz, C; Orleth, A; Ritschard, R; Albrecht, I; Herrmann, R; Christofori, G; Mamot, C,期刊:Clinical Cancer Research, 页码:454-464 , 文章类型: Article,,卷期:2012年18-2]
- Purpose: Angiogenesis is a key process in tumor progression. By binding VEGF, VEGF receptor-2 (VEGFR2) is a main signaling transducer in tumor-associated angiogenesis. Accordingly, therapeutic approaches against the VEGF...
- EpCAM/CD3-Bispecific T-cell Engaging Antibody MT110 Eliminates Primary Human Pancreatic Cancer Stem Cells
[作者:Cioffi, M; Dorado, J; Baeuerle, PA; Heeschen, C,期刊:Clinical Cancer Research, 页码:465-474 , 文章类型: Article,,卷期:2012年18-2]
- Purpose: Tumor-initiating cells with stem-like properties, also termed cancer stem cells (CSC), have been shown to sustain tumor growth as well as metastasis and are highly resistant to chemotherapy. Because pancreatic C...
- CPTH6, a Thiazole Derivative, Induces Histone Hypoacetylation and Apoptosis in Human Leukemia Cells
[作者:Trisciuoglio, D; Ragazzoni, Y; Pelosi, A; Desideri, M; Carradori, S; Gabellini, C; Maresca, G; Nescatelli, R; Secci, D; Bolasco, A; Bizzarri, B; Cavaliere, C; D'Agnano, I; Filetici, P; Ricci-Vitiani, L; Rizzo, MG; Del Bufalo, D,期刊:Clinical Cancer Research, 页码:475-486 , 文章类型: Article,,卷期:2012年18-2]
- Purpose: We previously identified novel thiazole derivatives able to reduce histone acetylation and histone acetyltransferase (HAT) activity in yeast. Among these compounds, 3-methylcyclopentylidene-[4-(4'-chlorophenyl) ...
- Tipping the Noxa/Mcl-1 Balance Overcomes ABT-737 Resistance in Chronic Lymphocytic Leukemia
[作者:Tromp, JM; Geest, CR; Breij, ECW; Elias, JA; van Laar, J; Luijks, DM; Kater, AP; Beaumont, T; van Oers, MHJ; Eldering, E,期刊:Clinical Cancer Research, 页码:487-498 , 文章类型: Article,,卷期:2012年18-2]
- Purpose: Chronic lymphocytic leukemia (CLL) cells in lymph nodes (LN), from which relapses are postulated to originate, display an antiapoptotic profile in contrast to CLL cells from peripheral blood (PB). The BH3 mimeti...
- VTX-2337 Is a Novel TLR8 Agonist That Activates NK Cells and Augments ADCC
[作者:Lu, HL; Dietsch, GN; Matthews, MAH; Yang, Y; Ghanekar, S; Inokuma, M; Suni, M; Maino, VC; Henderson, KE; Howbert, JJ; Disis, ML; Hershberg, RM,期刊:Clinical Cancer Research, 页码:499-509 , 文章类型: Article,,卷期:2012年18-2]
- Purpose: We aim to characterize VTX-2337, a novel Toll-like receptor (TLR) 8 agonist in clinical development, and investigate its potential to improve monoclonal antibody-based immunotherapy that includes the activation ...
- Iniparib Nonselectively Modifies Cysteine-Containing Proteins in Tumor Cells and Is Not a Bona Fide PARP Inhibitor
[作者:Liu, XS; Shi, Y; Maag, DX; Palma, JP; Patterson, MJ; Ellis, PA; Surber, BW; Ready, DB; Soni, NB; Ladror, US; Xu, AJ; Iyer, R; Harlan, JE; Solomon, LR; Donawho, CK; Penning, TD; Johnson, EF; Shoemaker, AR,期刊:Clinical Cancer Research, 页码:510-523 , 文章类型: Article,,卷期:2012年18-2]
- Purpose: PARP inhibitors are being developed as therapeutic agents for cancer. More than six compounds have entered clinical trials. The majority of these compounds are beta-nicotinamide adenine dinucleotide (NAD(+))-com...
- Loss of 18q22.3 Involving the Carboxypeptidase of Glutamate-like Gene Is Associated with Poor Prognosis in Resected Pancreatic Cancer
[作者:Lee, JH; Giovannetti, E; Hwang, JH; Petrini, I; Wang, QY; Voortman, J; Wang, YH; Steinberg, SM; Funel, N; Meltzer, PS; Wang, YS; Giaccone, G,期刊:Clinical Cancer Research, 页码:524-533 , 文章类型: Article,,卷期:2012年18-2]
- Purposes: Pancreatic cancer is the fourth leading cause of cancer-related death, and studies on the clinical relevance of its genomic imbalances are warranted. Experimental Design: Recurrent copy number alterations of cy...
- MicroRNA Molecular Profiles Associated with Diagnosis, Clinicopathologic Criteria, and Overall Survival in Patients with Resectable Pancreatic Ductal Adenocarcinoma
[作者:Jamieson, NB; Morran, DC; Morton, JP; Ali, A; Dickson, EJ; Carter, CR; Sansom, OJ; Evans, TRJ; McKay, CJ; Oien, KA,期刊:Clinical Cancer Research, 页码:534-545 , 文章类型: Article,,卷期:2012年18-2]
- Purpose: MicroRNAs (miRNA) have potential as diagnostic and prognostic biomarkers and as therapeutic targets in cancer. We sought to establish the relationship between miRNA expression and clinicopathologic parameters, i...
- Association of HER2/ErbB2 Expression and Gene Amplification with Pathologic Features and Prognosis in Esophageal Adenocarcinomas
[作者:Yoon, HH; Shi, Q; Sukov, WR; Wiktor, AE; Khan, M; Sattler, CA; Grothey, A; Wu, TT; Diasio, RB; Jenkins, RB; Sinicrope, FA,期刊:Clinical Cancer Research, 页码:546-554 , 文章类型: Article,,卷期:2012年18-2]
- Purpose: We examined the frequency, tumor characteristics, and prognostic impact of HER2 protein expression and gene amplification in patients with curatively resected esophageal adenocarcinoma (EAC). Experimental Design...
- Phase II, Open-Label, Randomized Trial of the MEK1/2 Inhibitor Selumetinib as Monotherapy versus Temozolomide in Patients with Advanced Melanoma
[作者:Kirkwood, JM; Bastholt, L; Robert, C; Sosman, J; Larkin, J; Hersey, P; Middleton, M; Cantarini, M; Zazulina, V; Kemsley, K; Dummer, R,期刊:Clinical Cancer Research, 页码:555-567 , 文章类型: Article,,卷期:2012年18-2]
- Purpose: To compare the efficacy and tolerability of the mitogen-activated protein (MAP)/extracellular signal-regulated (ERK) kinase (MEK) 1/2 inhibitor selumetinib versus temozolomide in chemotherapy-naive patients with...
- Phase I, Dose-Escalation Trial of the Oral Cyclin-Dependent Kinase 4/6 Inhibitor PD 0332991, Administered Using a 21-Day Schedule in Patients with Advanced Cancer
[作者:Flaherty, KT; LoRusso, PM; DeMichele, A; Abramson, VG; Courtney, R; Randolph, SS; Shaik, MN; Wilner, KD; O'Dwyer, PJ; Schwartz, GK,期刊:Clinical Cancer Research, 页码:568-576 , 文章类型: Article,,卷期:2012年18-2]
- Purpose: To identify the dose-limiting toxicity (DLT) and maximum tolerated dose (MTD) of the first-in-class, oral CDK4/6 inhibitor PD 0332991 administered once daily for 21 of 28 days (3/1 schedule) in patients with ret...
- A Genome-Wide Association Study of Overall Survival in Pancreatic Cancer Patients Treated with Gemcitabine in CALGB 80303
[作者:Innocenti, F; Owzar, K; Cox, NL; Evans, P; Kubo, M; Zembutsu, H; Jiang, C; Hollis, D; Mushiroda, T; Li, L; Friedman, P; Wang, LW; Glubb, D; Hurwitz, H; Giacomini, KM; McLeod, HL; Goldberg, RM; Schilsky, RL; Kindler, HL; Nakamura, Y; Ratain, MJ,期刊:Clinical Cancer Research, 页码:577-584 , 文章类型: Article,,卷期:2012年18-2]
- Background and Aims: Cancer and Leukemia Group B 80303 was a randomized, phase III study in patients with advanced pancreatic cancer treated with gemcitabine plus either bevacizumab or placebo. We prospectively collected...
|